Brian D. Robinson
YOU?
Author Swipe
View article: Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer
Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer Open
Castration-resistant prostate cancer (CRPC) is an aggressive disease exhibiting multiple epigenomic subtypes: androgen receptor-dependent CRPC-AR, and lineage plastic subtypes CRPC-SCL (stem cell-like), CRPC-WNT (Wnt-dependent), and CRPC-N…
View article: The Spatial Atlas of Human Anatomy (SAHA): A Multimodal Subcellular-Resolution Reference Across Human Organs
The Spatial Atlas of Human Anatomy (SAHA): A Multimodal Subcellular-Resolution Reference Across Human Organs Open
The Spatial Atlas of Human Anatomy (SAHA) represents the first multimodal, subcellular- resolution reference of healthy adult human tissues across multiple organ systems. Integrating spatial transcriptomics, proteomics, and histological fe…
View article: Supplementary Figure 3 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Figure 3 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Figure 3. Example case 3.
View article: Supplementary Information 1 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Information 1 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Information 1. Post-workshop survey questions.
View article: Data from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Data from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine (NE) prostate cancer (NEPC) occur in up to 15% to 20% of patients with castration-resistant prostate cancer (CRPC) as a mechanism of treatment …
View article: Supplementary Figure 2 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Figure 2 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Figure 2. Example case 2.
View article: Supplementary Figure 4 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Figure 4 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Figure 4. Example case 4.
View article: Supplementary Figure 1 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Supplementary Figure 1 from Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Supplementary Figure 1. Example case 1.
View article: Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate
Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate Open
The androgen receptor (AR) is central in prostate tissue identity and differentiation, and controls normal growth-suppressive, prostate-specific gene expression. It also drives prostate tumorigenesis when hijacked for oncogenic transcripti…
View article: Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies Open
Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine (NE) prostate cancer (NEPC) occur in up to 15% to 20% of patients with castration-resistant prostate cancer (CRPC) as a mechanism of treatment …
View article: Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer Open
Overcoming resistance to therapy is a major challenge in castration-resistant prostate cancer (CRPC). Lineage plasticity towards a neuroendocrine phenotype enables CRPC to adapt and survive targeted therapies. However, the molecular mechan…
View article: Data from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Data from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Background:Localized prostate tumors show significant spatial heterogeneity, with regions of high-grade disease adjacent to lower grade disease. Consequently, prostate cancer biopsies are prone to sampling bias, potentially leading to unde…
View article: Supplementary Figure 3 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Supplementary Figure 3 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Supplementary Figure 3 displays supplementary information on ancestry calling, genetically adjusted PSA Density, and polygenic risk scoring.
View article: Supplementary Figure 1 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Supplementary Figure 1 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Supplementary Figure 1 displays sequencing, variant capture, and imputation quality control metrics.
View article: Supplementary Table 2 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Supplementary Table 2 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Supplementary Table 2 reports demographic, clinical, and genetic summaries of the genetic analysis cohort.
View article: Supplementary Table 1 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Supplementary Table 1 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Supplementary Table 1 reports results of logistic regression with two clinical predictors of upgrading.
View article: Supplementary Table 4 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Supplementary Table 4 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Supplementary Table 4 reports results of DDR pathogenic variant carrier rate t-test analyses.
View article: Supplementary Table 5 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Supplementary Table 5 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Supplementary Table 5 reports results of genetic risk of upgrading score validation in the Upgrading Reference Set.
View article: Supplementary Table 3 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Supplementary Table 3 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Supplementary Table 3 reports per-sample genetic feature information in the genetic analysis cohort.
View article: Supplementary Figure 2 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Supplementary Figure 2 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Supplementary Figure 2 displays odds ratios and 95% confidence internals of significant predictors of upgrading in multivariable regression.
View article: Supplementary Figure 4 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Supplementary Figure 4 from Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort Open
Supplementary Figure 4 compares carrier rates of pathogenic variants in DDR genes between the study cohort and an external cohort.
View article: Supplementary Figure S20 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression
Supplementary Figure S20 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression Open
Supplementary Fig. S20. Immunofluorescence staining analysis of PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle
View article: Supplementary Figure S20 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression
Supplementary Figure S20 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression Open
Supplementary Fig. S20. Immunofluorescence staining analysis of PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle
View article: Supplementary Table S5 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression
Supplementary Table S5 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression Open
Supplementary Table S5. Complete listing and details of siRNA targeting sequences used for gene knockdown in Fig. 4A and Extended Data Fig. 3.
View article: Supplementary Figure S15 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression
Supplementary Figure S15 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression Open
Supplementary Fig. S15. Original unedited IB images for representative Western blots experiments (n-3) used in Figure 4D lower panels (RM-1-BM-EV/ inducible SPOPmuts)
View article: Supplementary Table S13 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression
Supplementary Table S13 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression Open
Supplementary Table S13. Quantification of each protein-specific band normalized to vinculin (macrophage cells (RAW264.7) mono- or cocultured with RM-1-BM EV or SPOPmut models under treatment with OLA, Fig. 5E).